04:33 AM EST, 03/06/2025 (MT Newswires) -- Ascentage Pharma ( AAPG ) said late Wednesday that China's National Medical Products Administration granted the company's olverembatinib drug a breakthrough therapy designation for combination with low-intensity chemotherapy for the first-line treatment of newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, a type of cancer.

The company is commercializing olverembatinib in China with Innovent Biologics.